For the roughly 37 million Americans living with diabetes, the disease is not an event but a calculation that repeats itself several times a day: what to eat, how much insulin to dose, when to walk, when to test. One Drop, a New York healthtech company founded in 2014, is betting that a phone in the pocket can carry more of that cognitive load than a clinician seen four times a year ever could.
The company, founded by Jeff Dachis, sells a consumer-facing diabetes management app that pairs glucose tracking with personalized coaching, drawing data from blood glucose meters, continuous glucose monitors (CGMs), and insulin pumps [CBInsights]. The product targets adults with type 1 and type 2 diabetes, a population for whom self-management is the defining clinical reality. Today's standard of care still leans heavily on quarterly endocrinology visits, A1C lab draws every three to six months, and patient-led logging in notebooks or device apps that rarely talk to each other. Continuous glucose monitors from Dexcom and Abbott have changed the data picture meaningfully over the past decade, but the interpretation gap, what to actually do with the readings, remains where most patients struggle.
That gap is the wedge One Drop is going after. The company describes itself as a precision health platform that combines continuous diagnostics, predictive analytics, and machine learning [LinkedIn]. In practice, that translates to a mobile app that ingests glucose readings, surfaces patterns, and pairs users with human and algorithmic coaching on food, exercise, and insulin response [CBInsights]. The direct-to-consumer business model puts One Drop in front of patients without requiring a payer contract first, a meaningful contrast with enterprise-sold diabetes programs from Omada Health, Onduo, and DarioHealth.
The Bayer bet
The most consequential validation of One Drop's technology has come from Bayer. The German pharmaceutical company licensed One Drop's data science, predictive capabilities, and mobile platform under a deal that accompanied a Series B investment, and the two companies have since co-developed an AI-powered platform aimed at preventing cardiovascular disease [Captured sources, refs 12-14]. Bayer also took the licensing rights into therapeutic areas outside diabetes, an unusual structure that suggests the pharma believed the underlying engine generalized beyond glucose.
Series A (2015) | 8 | $M
Later round (Bayer-era) | 40 | $M
The Series A closed in June 2015 at roughly $8 million [Crunchbase], with a subsequent round reported at $40 million tied to the Bayer relationship [Crunchbase; PitchBook]. For a company of One Drop's vintage, the capital base is modest by current digital health standards, where rivals like Omada have raised several hundred million dollars. That comparison cuts two ways: it constrains marketing reach, but it also means One Drop has not had to chase the headcount and burn profile that has forced layoffs across the category in the last two years.
Why the bet could be big
Diabetes is one of the few chronic conditions where the economic case for software is unambiguous. Poorly controlled diabetes drives hospitalizations, amputations, dialysis, and cardiovascular events, all of which are expensive and largely preventable with better day-to-day management. CGM penetration is climbing, Medicare expanded coverage in recent years, and the FDA has cleared over-the-counter CGMs from Dexcom and Abbott, putting continuous data into the hands of millions of people who were previously fingerstick-only. Every one of those new CGM users is a potential customer for an interpretation layer.
One Drop's bet is that the interpretation layer should be a consumer brand, not a hospital workflow tool. The company has invested in direct outreach to patients, including television advertising, to build a recognizable name in a category that has historically been mediated by clinicians and pharmacy benefit managers [Fierce Pharma]. In 2018, industry analysts ranked One Drop among the top three digital diabetes care providers worldwide [PRNewswire, 2018], a notable marker for a then four-year-old startup competing against incumbents with hardware franchises.
Founder and traction
Jeff Dachis, One Drop's founder, was diagnosed with type 1 diabetes as an adult and has spoken publicly about building the product he wished existed for himself [pharmaphorum]. He previously co-founded Razorfish, the digital agency that became one of the defining firms of the first internet era, giving him an unusual blend of consumer marketing instinct and operating experience for a healthtech founder. The Bayer partnership, structured as both an equity investment and a technology license, is the clearest external signal that One Drop's machine learning work has been independently evaluated by a sophisticated buyer [Captured sources, refs 12-14].
What bears say, what bulls answer
The most credible concern is competitive density. The diabetes management space includes Omada Health, DarioHealth, Onduo, Glooko, MySugr (owned by Roche), and the in-house apps of every major CGM and pump maker, including Dexcom, Tandem, and Medtronic. Several of those rivals have hardware ecosystems or payer contracts that give them structural distribution advantages a consumer app does not. The bull answer is that One Drop chose a different lane on purpose: by being device-agnostic and consumer-billed, it can sit on top of any CGM the patient happens to wear, and its Bayer relationship gives it a pharma channel that the pure-play software competitors do not have [refs 12-14]. Whether that positioning translates into durable subscriber economics is the question the next twelve months will answer.
What to watch
The near-term milestones worth tracking are the cardiovascular product co-developed with Bayer, which would extend One Drop beyond diabetes into a much larger at-risk population, and any disclosure of clinical outcomes data submitted for peer review. Digital health companies that publish A1C reductions in indexed journals tend to get taken more seriously by payers, and the diabetes category has matured to the point where claims without published evidence increasingly bounce off procurement desks. A renewed funding round, or a deeper structural deal with Bayer, would also clarify whether One Drop's next chapter is independent growth or strategic integration into a larger pharma platform.
For now, the company is doing something genuinely difficult: trying to make a daily disease less exhausting for the people who live with it, one glucose reading at a time.
Pulse Raman, Health and Bio Correspondent